Breathe Well Live Well
 GPB |
Glaxo Executives Cited in Case Now Lead Sanofi, Actelion
Businessweek Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies. Glaxo Settlement Pulls Back Curtain On Drug Marketing |
View full post on asthma – Google News
|
Glaxo Settlement Pulls Back Curtain On Drug Marketing
NPR (blog) The government alleged that Glaxo promoted Advair, an asthma remedy combining two drugs, for use as a first-choice treatment for just about anybody with asthma. The Food and Drug Administration, concerned about risks, took a much narrower view and … |
View full post on asthma – Google News
|
Glaxo Settlement Pull Back Curtain On Drug Marketing
NPR (blog) The government alleged that Glaxo promoted Advair, an asthma remedy combining two drugs, for use as a first-choice treatment for just about anybody with asthma. The Food and Drug Administration, concerned about risks, took a much narrower view and … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
Glaxo to Hike Stake in Theravance
Zacks.com The increased holding by the pharma major reflects its confidence in the Relovair program, under which the companies are looking to replace one of Glaxo's best selling drugs Advair by evaluating treatment options for asthma and chronic obstructive … GlaxoSmithKline Boosts Stake In Theravance To 27% GlaxoSmithKline to Increase Its Ownership in Theravance Glaxo Lifts Theravance Stake |
View full post on asthma – Google News
|
Mixed Data for Glaxo & THRX Drug
Zacks.com GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced top-line data from phase III studies conducted with their pipeline candidate, Relovair, for chronic obstructive pulmonary disease (COPD) and asthma. Relovair is a combination of … Breathe Easy: Program Complete, Data Solid |
View full post on asthma – Google News
|
Glaxo and Theravance Suffer Setback
Zacks.com In the asthma studies, Relovair showed an encouraging efficacy profile but was associated with several side-effects, like headache, nasopharyngitis, upper respiratory tract infection, bronchitis, cough, oropharyngeal pain and influenza. … |
View full post on asthma – Google News
 Visit Bulgaria |
Theravance Falls Most in 3 Years After Glaxo Drug Fails
BusinessWeek The company, based in South San Francisco, California, said in a statement today that Relovair, its drug for asthma and chronic obstructive pulmonary disease, proved no better than Glaxo's Seretide in a clinical trial. Relovair is “the most important … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Glaxo on the slide after trials setback for asthma drug Theravance Shares Slide on Lung Drug Deaths |
View full post on asthma – Google News
 Reuters UK |
Glaxo on the slide after trials setback for asthma drug
Evening Standard But clinical trials have not shown the new treatment to be better than GSK's flagship asthma drug Advair. "The results aren't a home run but look adequate for filing and approval," said pharma analyst Emmanuel Papadakis at Collins Stewart. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … GSK to seek approval of Theravance lung drug For COPD, Glaxo intends to submit regulatory applications in the US and Europe … |
View full post on asthma – Google News
|
Glaxo set to submit Relovair to regulatory authorities
ShareCast Additionally, all but one of the pivotal studies in patients with asthma have been completed. For COPD, Glaxo intends to submit regulatory applications in the US and Europe in mid-2012. For asthma, Glaxo plans to submit an application in Europe in … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … |
View full post on asthma – Google News
|
Exclusive – Glaxo R&D boss says Advair safe from generic
Reuters UK L) $8 billion (5 billion pounds)-a-year Advair treatment for asthma and smoker's cough can hope to capture only "a very small fraction" of its sales, the British drugmaker's research chief said on Tuesday. Advair, an inhaler which delivers two drugs … |
View full post on asthma – Google News